Display options
Cite
Lin YC, Wu X, Zhou XQ, et al. Cytochrome P450 2E1 RsaI/PstI polymorphism is associated with urologic cancer risk: evidence from a meta-analysis. Int J Clin Exp Med. 2015;8(6):8927-37
Lin, Y. C., Wu, X., Zhou, X. Q., Ren, R., Su, Z. X., & Liu, C. X. (2015). Cytochrome P450 2E1 RsaI/PstI polymorphism is associated with urologic cancer risk: evidence from a meta-analysis. International journal of clinical and experimental medicine, 8(6), 8927-37.
Lin, You-Cheng, et al. "Cytochrome P450 2E1 RsaI/PstI polymorphism is associated with urologic cancer risk: evidence from a meta-analysis." International journal of clinical and experimental medicine vol. 8,6 (2015): 8927-37.
Lin YC, Wu X, Zhou XQ, Ren R, Su ZX, Liu CX. Cytochrome P450 2E1 RsaI/PstI polymorphism is associated with urologic cancer risk: evidence from a meta-analysis. Int J Clin Exp Med. 2015 Jun 15;8(6):8927-37. eCollection 2015. PMID: 26309545; PMCID: PMC4538138.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2015 Jun 15;8(6):8927-37. eCollection 2015.

Cytochrome P450 2E1 RsaI/PstI polymorphism is associated with urologic cancer risk: evidence from a meta-analysis.

International journal of clinical and experimental medicine

You-Cheng Lin, Xun Wu, Xue-Qiong Zhou, Rui Ren, Ze-Xuan Su, Chun-Xiao Liu

Affiliations

  1. Department of Urology, Fujian Provincial Clinical College, Fujian Medical University Fuzhou, China ; Department of Urology, Zhujiang Hospital, Southern Medical University Guangzhou, China.
  2. Department of Urology, The First Affiliated Hospital of Jinan University Guangzhou, China ; Department of Anatomy, School of Basic Medicine Science, Southern Medical University Guangzhou, China.
  3. Department of Occupational Health and Occupational Medicine, School of Public Health and Tropical Medicine, Southern Medical University Guangzhou, China.
  4. Department of Urology & Andrology, Zhongshan City People's Hospital Zhongshan, China.
  5. Department of Urology, Zhujiang Hospital, Southern Medical University Guangzhou, China.

PMID: 26309545 PMCID: PMC4538138

Abstract

Cytochrome P450 2E1 (CYP2E1) is involved in the metabolic activation of various carcinogens. CYP2E1 RsaI/PstI polymorphism has been identified in urologic cancer patients, while studies of the polymorphism have shown inconclusive trends in the risk of urologic cancers. Therefore, we performed this systematic review to provide a complete picture and conducted a meta-analysis to derive a precise estimation. We searched PubMed, Embase and Web of Science to identify eligible studies up to December 15, 2014. 12 studies with 2712 cases and 2977 controls were included in the meta-analysis.The odds ratio with a 95% confidence interval was used to assess the strength of associations. We observed that the c2 allele of CYP2E1 RsaI/PstI polymorphism was associated with a decreased risk of urologic cancer under all genetic models (c2 vs. c1: OR = 0.742, 95% CI = 0.659-0.835); c2c2 vs. c1c1: OR = 0.516, 95% CI = 0.357-0.745; c1c2 vs. c1c1: OR = 0.748, 95% CI = 0.748 (0.648-0.863; c2c2 + c1c2 vs. c1c1: OR = 0.722, 95% CI = 0.629-0.829; c2c2 vs. c1c1 + c1c2: OR = 0.578, 95% CI = 0.401-0.832). In the subgroup analysis by cancer type, statistically significant associations were found in urothelial cancer in all genetic models. When stratified by ethnicity, a same trend was also indicated in Asians in all genetic models.To conclude, our results support the conclusion that the CYP2E1 RsaI/PstI polymorphism may be associated with urologic cancer susceptibility. The c2 allele is a low-penetrance risk factor for urologic cancer development.

Keywords: Cytochrome P450 2E1; meta-analysis; polymorphism; susceptibility; urologic cancer

References

  1. Mutat Res. 2001 Oct 1;482(1-2):11-9 - PubMed
  2. Asian Pac J Cancer Prev. 2014;15(13):5411-6 - PubMed
  3. Int J Mol Epidemiol Genet. 2013 Nov 28;4(4):207-17 - PubMed
  4. Eur Urol. 2013 Feb;63(2):234-41 - PubMed
  5. Eur J Cancer Prev. 2003 Jun;12(3):205-11 - PubMed
  6. Int J Clin Pharmacol Ther. 1998 Sep;36(9):463-8 - PubMed
  7. Cancer Lett. 2001 Apr 26;165(2):171-7 - PubMed
  8. Carcinogenesis. 1992 Oct;13(10 ):1789-94 - PubMed
  9. Eur J Cancer. 2010 Mar;46(4):758-64 - PubMed
  10. Occup Med (Lond). 2002 May;52(3):157-64 - PubMed
  11. Biometrics. 1994 Dec;50(4):1088-101 - PubMed
  12. Carcinogenesis. 1998 Aug;19(8):1329-32 - PubMed
  13. FASEB J. 1992 Jan 6;6(2):724-30 - PubMed
  14. J Intern Med. 2002 Sep;252(3):206-24 - PubMed
  15. Environ Health Perspect. 2010 Nov;118(11):1545-50 - PubMed
  16. Int J Clin Pharmacol Ther. 2000 Jan;38(1):30-4 - PubMed
  17. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):89-104 - PubMed
  18. JAMA. 2008 May 28;299(20):2423-36 - PubMed
  19. Pharmacogenetics. 1994 Aug;4(4):185-92 - PubMed
  20. Urology. 2013 Feb;81(2):277-81 - PubMed
  21. Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R103-21 - PubMed
  22. Asian Pac J Cancer Prev. 2012;13(10):4915-21 - PubMed
  23. Carcinogenesis. 1996 Sep;17(9):1923-9 - PubMed
  24. Carcinogenesis. 2012 Nov;33(11):2108-18 - PubMed
  25. Asian Pac J Cancer Prev. 2005 Jan-Mar;6(1):6-9 - PubMed
  26. Int J Urol. 2008 Mar;15(3):216-21 - PubMed
  27. Am J Clin Nutr. 2008 May;87(5):1428-38 - PubMed
  28. Asian Pac J Cancer Prev. 2013;14(1):179-82 - PubMed
  29. Exp Ther Med. 2012 Nov;4(5):938-948 - PubMed
  30. Oral Dis. 2014 Oct;20(7):644-9 - PubMed
  31. Lancet Oncol. 2014 Apr;15(5):489-538 - PubMed
  32. Toxicol Appl Pharmacol. 2009 Nov 15;241(1):111-8 - PubMed
  33. Cancer. 2000 Aug 1;89(3):630-9 - PubMed
  34. Int J Clin Exp Pathol. 2009;2(2):182-9 - PubMed
  35. J Surg Oncol. 2013 Feb;107(2):221-6 - PubMed
  36. Pharmacogenetics. 2003 Jun;13(6):349-55 - PubMed
  37. Zhonghua Nan Ke Xue. 2009 Jan;15(1):7-11 - PubMed
  38. Asian Pac J Cancer Prev. 2014;15(12):4977-82 - PubMed
  39. Int J Urol. 2006 Jun;13(6):773-80 - PubMed
  40. World J Gastroenterol. 2010 Jun 21;16(23):2949-53 - PubMed
  41. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1696-702 - PubMed
  42. J Biochem. 1991 Oct;110(4):559-65 - PubMed
  43. J Natl Cancer Inst. 1999 Dec 1;91(23):2038-44 - PubMed
  44. Arch Esp Urol. 2014 Jun;67(5):373-82 - PubMed
  45. Cancer Res. 1996 Sep 1;56(17):3915-25 - PubMed
  46. Nat Rev Urol. 2010 May;7(5):245-57 - PubMed
  47. Lancet. 2002 Oct 12;360(9340):1155-62 - PubMed
  48. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  49. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  50. Exp Toxicol Pathol. 1998 Sep;50(4-6):425-31 - PubMed
  51. Lancet. 1982 Oct 16;2(8303):842-5 - PubMed
  52. Mol Biol Rep. 2011 Apr;38(4):2409-16 - PubMed
  53. Int J Clin Exp Pathol. 2013 Sep 15;6(10):1984-98 - PubMed
  54. Int J Clin Exp Pathol. 2010 Dec 13;4(1):58-73 - PubMed
  55. PLoS One. 2012;7(11):e48265 - PubMed

Publication Types